Cumberland Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $47.3M | Buy |
39,407
+3,172
| +9% | +$3.24M | 3.06% | 8 |
|
|
2026
Q1 | $33.3M | Buy |
36,235
+2,110
| +6% | +$2.14M | 2.53% | 12 |
|
|
2025
Q4 | $36.7M | Buy |
34,125
+2,250
| +7% | +$2.15M | 2.25% | 15 |
|
|
2025
Q3 | $24.3M | Sell |
31,875
-4,727
| -13% | -$3.52M | 1.59% | 21 |
|
|
2025
Q2 | $28.5M | Buy |
36,602
+1,373
| +4% | +$1.07M | 1.98% | 17 |
|
|
2025
Q1 | $29.1M | Buy |
35,229
+11,956
| +51% | +$9.95M | 2.24% | 17 |
|
|
2024
Q4 | $18M | Buy |
23,273
+1,289
| +6% | +$1.07M | 1.25% | 26 |
|
|
2024
Q3 | $19.5M | Buy |
21,984
+13,942
| +173% | +$12.5M | 1.35% | 25 |
|
|
2024
Q2 | $7.28M | Buy |
8,042
+1,210
| +18% | +$968K | 0.53% | 43 |
|
|
2024
Q1 | $5.32M | Sell |
6,832
-1,193
| -15% | -$849K | 0.39% | 52 |
|
|
2023
Q4 | $4.61M | Sell |
8,025
-4,220
| -34% | -$2.46M | 0.42% | 54 |
|
|
2023
Q3 | $6.58M | Sell |
12,245
-278
| -2% | -$143K | 0.63% | 33 |
|
|
2023
Q2 | $5.87M | Buy |
12,523
+7,070
| +130% | +$2.96M | 0.54% | 41 |
|
|
2023
Q1 | $1.87M | Sell |
5,453
-14,050
| -72% | -$4.74M | 0.18% | 86 |
|
|
2022
Q4 | $7.13M | Sell |
19,503
-3,530
| -15% | -$1.25M | 0.75% | 28 |
|
|
2022
Q3 | $7.45M | Buy |
23,033
+2,000
| +10% | +$634K | 0.79% | 32 |
|
|
2022
Q2 | $6.82M | Buy |
21,033
+325
| +2% | +$97.6K | 0.65% | 39 |
|
|
2022
Q1 | $5.93M | Buy |
20,708
+12,115
| +141% | +$3.12M | 0.45% | 52 |
|
|
2021
Q4 | $2.37M | Buy |
+8,593
| New | +$2.18M | 0.17% | 93 |
|
|
2021
Q1 | – | Sell |
-7,545
| Closed | -$1.27M | – | 188 |
|
|
2020
Q4 | $1.27M | Buy |
7,545
+2,250
| +42% | +$336K | 0.11% | 106 |
|
|
2020
Q3 | $784K | Buy |
+5,295
| New | +$819K | 0.08% | 112 |
|
|
2020
Q2 | – | Sell |
-5,490
| Closed | -$762K | – | 165 |
|
|
2020
Q1 | $762K | Sell |
5,490
-1,900
| -26% | -$261K | 0.09% | 108 |
|
|
2019
Q4 | $971K | Sell |
7,390
-65
| -0.9% | -$7.53K | 0.09% | 116 |
|
|
2019
Q3 | $834K | Buy |
7,455
+1,865
| +33% | +$208K | 0.08% | 111 |
|
|
2019
Q2 | $619K | Sell |
5,590
-562
| -9% | -$66.2K | 0.06% | 126 |
|
|
2019
Q1 | $798K | Buy |
6,152
+1,332
| +28% | +$162K | 0.08% | 114 |
|
|
2018
Q4 | $558K | Buy |
4,820
+920
| +24% | +$103K | 0.06% | 125 |
|
|
2018
Q3 | $419K | Hold |
3,900
| – | – | 0.04% | 148 |
|
|
2018
Q2 | $333K | Buy |
+3,900
| New | +$320K | 0.03% | 167 |
|
Other funds holding LLY
Cumberland Partners's LLY Position: Q2 2026 in Review
Cumberland Partners increased its Eli Lilly (LLY) stake by 8.8% in Q2 2026, buying an estimated $3.24M and bringing the position to 39,407 shares worth $47.3M. The position accounts for 3.06% of the portfolio, ranked #8.
Cumberland Partners first reported a position in LLY in Q2 2018 and has held it in 29 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Cumberland Partners held 39,407 shares of Eli Lilly worth $47.3M as of Q2 2026.
- Cumberland Partners bought 3,172 Eli Lilly shares in Q2 2026, an estimated $3.24M.
- Eli Lilly made up 3.06% of Cumberland Partners's portfolio in Q2 2026, its #8 holding.
- Cumberland Partners first reported a position in Eli Lilly in Q2 2018 and has held it in 29 quarters since.
- 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Cumberland Partners's 13F filing for Q2 2026, filed 6 Aug 2026.